Recent investigations into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing promising effects in managing obesity and type non-insulin-dependent diabetes. Preclinical information suggest a unique https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/